Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower od ...

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

In the high-stakes world of drug development, a pill is never just a pill. Every oral drug that reaches the market has passed through a tightly managed series of steps—none more critical, or more ...